Emerging evidence from clinical trials investigating CTLA-4 inhibition in lung cancer and other malignancies suggests that discontinuing therapy due to a TRAE or requiring immunosuppression to manage immune-mediated toxicities does not impact OS negatively42–44. Here, CTLA4 is linked to lung cancer.